Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides vaccines and treatments in immunology and inflammation, rare diseases, neurology, and oncology, including pediatric vaccines for poliomyelitis, pertussis, and Hib, as well as respiratory syncytial virus protection and hexavalent combination vaccines covering hepatitis A, typhoid, yellow fever, and rabies. The company has collaboration and license agreements with Exscientia, ABL Bio, Innate Pharma, Atomwise, Insilico Medicine, Kymera Therapeutics, Nurix Therapeutics, Denali Therapeutics, Adagene, Scribe Therapeutics, Teva Pharmaceuticals, and Provention Bio. Formerly known as Sanofi-Aventis, it changed its name to Sanofi in May 2011, was incorporated in 1994, and is headquartered in Paris, France.
AstraZeneca's Tozorakimab Cuts COPD Flare-Ups by 30% in Late-Stage Trials
AstraZeneca PLC released full results from two successful late-stage trials of tozorakimab, an experimental chronic obstructive pulmonary disease drug that reduced moderate and severe flare-ups by roughly 30% across a broad patient population. The two trials showed reductions in moderate-to-severe COPD exacerbations of 29% to 34%, with the highest-eosinophil subgroup seeing a 43% reduction, and benefits appearing regardless of eosinophil levels, smoking status, or disease severity. The biologic, which blocks the inflammatory protein IL-33, is under priority review at the FDA with a decision expected in the first quarter of 2027, and AstraZeneca forecasts more than $5 billion in peak annual sales, an estimate CEO Pascal Soriot said the drug's commercial potential could exceed. AstraZeneca believes tozorakimab could reach a broader group of COPD patients than existing biologics such as Regeneron and Sanofi's Dupixent and GSK's Nucala, which only target those with high eosinophil counts. The company's oncology and respiratory portfolio made $14.1 billion in first-half 2026 revenue, up 15% year over year, as AstraZeneca targets $80 billion in annual revenue by 2030, though the drug still needs FDA approval and faces patent-expiry pressure on established products including Farxiga and Brilinta.
Cheplapharm to acquire 20 medicines and three Sanofi sites
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi. Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm, expanding on a working relationship between the two companies that began in 2014. The selected medicines, including Lovenox/Clexane (enoxaparin), are intended to benefit from Cheplapharm's operational approach, and the companies stated that different operating models may better address the manufacturing, regulatory and commercial characteristics of established treatments compared to new medicines. Cheplapharm will acquire production sites located in Csanyikvölgy in Hungary, Jurong in Singapore, and Ploërmel in France, which employ approximately 400, 100, and 65 employees, respectively, with existing employment terms and collective agreements expected to remain in place. The planned commercial transition is targeted to begin in the first quarter of 2027, with full completion anticipated by the third quarter of 2027, subject to regulatory approvals and employee consultations, and the transaction is not expected to affect Sanofi's financial guidance for 2026.
Teva Says Pivot to Growth Accelerating as Branded Drugs and Biosimilars Expand
Teva Pharmaceutical Industries said its "Pivot to Growth" strategy has entered its second phase, with management pointing to branded-medicine momentum, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet. Speaking at a Morgan Stanley event, President and Chief Executive Officer Richard Francis said the strategy, launched in 2023, rests on four pillars: delivering on the growth engine, stepping up innovation, creating a generics powerhouse, and focusing the business and capital allocation. Francis said Teva has cut debt and secured investment-grade ratings from all three major agencies more than a year ahead of its projection, completed an oversubscribed refinancing in the prior week, and converted ADS shares into ordinary shares to broaden investor access. He reiterated confidence that AUSTEDO can eventually exceed $3 billion in sales, ahead of the prior $2.5 billion target, and said AJOVY is approaching the $1 billion threshold faster than expected, while UZEDY and long-acting olanzapine together represent a $1.5 billion to $2 billion opportunity. Teva has 11 biosimilars on the market and expects to add roughly nine more by the end of the decade, and Francis said the company is on track to exceed its $800 million biosimilars target for 2027 a year early. Chief Medical Officer Eric Hughes said the TL1A therapy duvakitug, developed with Sanofi for ulcerative colitis and Crohn's disease, showed the highest phase 2 results reported for the class, and that ecopipam, a first-in-class D1 antagonist for Tourette's disease, received priority review with a potential launch in the first half of 2027.
Novartis's Remibrutinib Beats Sanofi's Aubagio in Two Late-Stage MS Trials
Novartis's oral drug remibrutinib outperformed Sanofi's older multiple-sclerosis treatment teriflunomide in reducing relapses across two late-stage studies, REMODEL-1 and REMODEL-2, marking the first major success from three closely watched pipeline programs expected to produce clinical data in 2026. Novartis said remibrutinib also showed clinically meaningful results in slowing disability progression and was well tolerated with no liver-safety issues, a key point for a Bruton's tyrosine kinase inhibitor, a class that has previously faced regulatory problems over liver toxicity. UBS analyst Matt Weston called it potentially a best-in-class oral treatment. Novartis plans to submit remibrutinib for global regulatory approval and will present full results at a medical conference in Toronto; the drug is already approved for one chronic inflammatory skin condition involving severe hives, sold as Rhapsido, which generated $64 million in second-quarter sales. Analysts estimate remibrutinib could generate as much as $9 billion in peak annual sales across all indications, though that figure assumes successful development and approvals in multiple sclerosis, additional skin disease, and food allergies, and two patients died during the studies, which analysts said were unrelated to treatment but still intend to examine in the detailed safety data. Remibrutinib is the first of three programs, alongside pelacarsen and del-desiran, collectively seen generating more than $10 billion in peak annual sales as Novartis faces generic pressure on its blockbuster heart-failure medicine Entresto.
Ulcerative Colitis Market to Reach $9.4B by 2036, Late-Stage Drugs Advance
DelveInsight projects the ulcerative colitis market across the seven major markets—the US, EU4, UK, and Japan—will grow from approximately USD 9.4 billion in 2025 at a CAGR of 7.6% through 2036, driven by novel targeted therapies and a robust pipeline of late-stage candidates. Among these, Abivax's obefazimod, a first-in-class oral miR-124 enhancer, met its primary endpoint in Phase III ABTECT induction studies, with a pooled placebo-adjusted clinical remission rate of 16.4% at Week 8. Merck's tulisokibart, acquired via Prometheus Biosciences, achieved clinical remission in the Phase 3 ATLAS-UC study, while Roche's afimkibart, from its $7.1 billion Telavant acquisition, showed a 35% remission rate in Phase IIb TUSCANY-2. Johnson & Johnson and Protagonist Therapeutics' icotrokinra, a first-in-class oral IL-23 receptor antagonist, met its primary endpoint in the Phase 2b ANTHEM-UC trial, and Teva and Sanofi's duvakitug, backed by a $400 million Blackstone funding deal, is in Phase III. These therapies target unmet needs in moderate-to-severe disease, with the market shifting toward IL-23 inhibitors and oral advanced therapies, though biosimilars and established anti-TNFs remain widely used.
Moderna Gets FDA Approvals for Updated COVID and First mRNA Flu Shots
Moderna received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant, as well as mFlusiva, its first mRNA-based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark the first FDA-authorized mRNA flu shot for older adults. The company, a US-based biotechnology firm developing messenger RNA medicines, sees these approvals as reinforcing its regulatory momentum and diversifying its respiratory offerings against competitors like Pfizer and Novavax in COVID and Sanofi and GSK in flu. However, analysts note that respiratory shots still depend on annual uptake, pricing, and pharmacy stocking, so the key question is how far these launches reduce reliance on a narrow set of seasonal products.
Sanofi has permanently halted its Phase 3 RSV vaccine trial in infants and toddlers following a serious adverse event involving an infant death, which was later linked to an underlying health condition that should have excluded the child from the study. The decision has drawn heightened regulatory attention, including Freedom of Information Act requests to the FDA, and raises concerns about RSV vaccine safety in very young children. This move affects Sanofi's vaccine R&D pipeline and has scientific and reputational implications in the pediatric vaccine market, potentially influencing investor views on its broader role in childhood infectious disease prevention.
Pfizer won FDA approval Thursday for its updated Comirnaty COVID vaccine, with deliveries starting immediately and doses expected in pharmacies and clinics within days. The vaccine, developed with BioNTech, is now limited to adults 65 and older and higher-risk patients aged 5 to 64, a much smaller market than the pandemic-era rollout. Comirnaty has distributed over five billion doses worldwide, but the new seasonal demand is uncertain. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine. Shares traded at $27.9079 on August 28, 5.27% above the GF Value estimate of $26.51, indicating a premium before uptake and reimbursement details emerge.
Novavax Partners Secure Nuvaxovid Approvals for 2026-2027 Season
Novavax's partners have received approvals for the XFG-adapted Nuvaxovid vaccine for the 2026-2027 vaccination season in the U.S., European Union, and Japan, positioning the company to earn royalties on net sales in these markets. The approvals, announced August 28, 2026, cover the protein-based, non-mRNA vaccine, which has demonstrated a favorable tolerability profile in Sanofi's Phase 4 COMPARE study. Novavax's largest partner, Sanofi, will lead commercial activities in most major markets, including an expanded U.S. campaign and launches in Germany, Canada, and other international markets from 2026 onward. Takeda, which commercializes Nuvaxovid in Japan, saw the vaccine become the second-most used COVID-19 vaccine there in the 2025-2026 season, with delivery volumes and site numbers increasing significantly year over year. Under the collaboration and license agreements, Novavax is eligible for ongoing royalties and annual milestones tied to regulatory approvals, without carrying its own commercial infrastructure.
The global cytotoxic drugs market is projected to grow from $16.21 billion in 2026 to $21.06 billion by 2031, at a compound annual growth rate of 5.37%, according to a new report from ResearchAndMarkets.com. Rising cancer incidence, earlier diagnosis, expanded reimbursement, and growing demand in emerging economies are driving the market. In 2025, the market was valued at $15.38 billion, with parenteral drugs holding a 68.87% share, while oral drugs are expected to grow faster at an 8.79% CAGR. Alkylating agents led with a 30.10% share in 2025, but antimetabolites are forecast to grow fastest at 7.02% CAGR. North America accounted for 42.15% of revenue in 2025, while Asia-Pacific is projected to grow at 10.07% CAGR, supported by China's approval of 228 drugs in 2024, 37% of which were antineoplastics. Key players include Pfizer, Roche, Novartis, AstraZeneca, and Sanofi.
AbbVie Takes On $8 Billion in Debt to Fund Apogee Therapeutics Acquisition
AbbVie is taking on $8 billion in debt to finance its $10.6 billion acquisition of Apogee Therapeutics, a deal expected to close in the third quarter pending regulatory approvals. The company said the acquisition will not boost adjusted earnings per share until 2032 and will cause $0.14 in dilution this year, lowering its adjusted EPS guidance to a range of $13.87 to $14.07. AbbVie plans to maintain its dividend, having raised it by 5.5% to $1.73 per share this year, and aims to preserve its A2/A- credit rating while reducing net leverage to about 2 times within two to three years after closing. The deal is centered on Apogee's lead drug candidate, Zumilokibart, a monoclonal antibody targeting interleukin-13 for atopic dermatitis with a three- to six-month dosing interval that could compete with Sanofi's Dupixent, which generated 15.7 billion euros in 2025 sales. AbbVie reported second-quarter revenue of $16.9 billion, up 10.2%, and earnings per share of $2.03, a 290% increase from the prior year.
Biotech Stocks Hit 52-Week Highs on Earnings and Pipeline Progress
Several biotech stocks reached 52-week highs on August 7, 2026, driven by quarterly results and clinical advancements. Delcath Systems surged over 22% to $15.62 after reporting second-quarter net revenues of $29.1 million, up from $24.2 million a year earlier, with HEPZATO product revenue growing about 30% to $27.1 million across roughly 31 active treatment centers. Alto Neuroscience rose to a 52-week high of $29.48 following last month's registered direct offering that raised an estimated $100 million to advance its lead candidate ALTO-207 toward a Phase 3 trial. Hemab Therapeutics hit $53.60 after positive Phase 2 data showed Sutacimig reduced the mean annualized treated bleeding rate by 84% in Glanzmann thrombasthenia and Factor VIII deficiency, alongside encouraging interim Phase 2 results for HMB-002 in Von Willebrand's disease. Monopar Therapeutics reached $124.31 on the back of positive Phase 3 results for ALXN1840 in Wilson disease, which earned a Rare Pediatric Disease voucher from the FDA, with an NDA submission planned by mid-2026. Nurix Therapeutics climbed to $25.49 after receiving a $10 million milestone payment from Sanofi for the Phase 1 initiation of NX-3911 and announcing with Roche the first patient enrolled in the Phase 3 DAYBreak CLL-306 trial evaluating Bexobrutideg in relapsed/refractory chronic lymphocytic leukemia.
Novavax Raises 2026 Revenue Guidance to $235-$275 Million on Matrix-M Demand
Novavax raised its full-year 2026 revenue guidance to between $235 million and $275 million, driven by strong demand for its Matrix-M adjuvant from commercial partners. The company reported a net loss of $53 million in the second quarter on total revenue of $57 million, a sharp decline from $239 million a year earlier due to the absence of one-time milestone payments. Novavax is on track to reduce operating expenses by approximately 90% from peak levels and reiterated its goal of reaching non-GAAP profitability as early as 2028. The Sanofi partnership is advancing, with Sanofi in advanced regulatory discussions for a Phase 3 combination COVID-19/influenza vaccine study, which would trigger a $125 million milestone payment. Novavax also expects a $75 million manufacturing tech transfer milestone from Sanofi by mid-2027, extending its cash runway into 2029.
Nurix Therapeutics Receives $10 Million Milestone as Phase 3 Trial Begins
Nurix Therapeutics announced a $10 million milestone payment from Sanofi triggered by the first-in-human trial of an oral STAT6 degrader, bringing total receipts under that collaboration to about $139 million. The company also enrolled the first patient in a pivotal global Phase 3 trial of bexobrutideg for relapsed or refractory chronic lymphocytic leukemia, conducted in partnership with Roche. The Sanofi deal leaves Nurix eligible for roughly $453 million in additional milestones plus potential royalties, while the Roche-partnered study marks a move into registrational testing. Both programs advance Nurix's clinical pipeline in targeted protein degradation and signal that large pharmaceutical partners are committing resources to its drug candidates.
NAD Finds Some DUPIXENT Claims Supported, Recommends Sanofi Modify or Discontinue Others
The National Advertising Division found certain claims for Sanofi’s eczema treatment DUPIXENT supported but recommended the company modify or discontinue other claims following a challenge by Galderma. NAD determined that claims about staying ahead of eczema, blocking a key source of inflammation, healing skin from within, and 90% clearer skin were supported, while an animated mechanism-of-action video likely conveyed an unsupported message. The division recommended that Sanofi modify or discontinue television claims about long-lasting clearer skin and fast itch relief to clearly disclose how many patients achieved the results or that the results reflected treatment with DUPIXENT combined with topical corticosteroids. NAD also found that a prescriber-facing claim of itch reduction starting as early as day 2 was not supported by the post hoc analysis and should be discontinued or modified. Sanofi stated it will comply with NAD’s recommendations.
Sanofi’s MenQuadfi approved in EU for infants from six weeks of age
The European Commission has approved Sanofi’s MenQuadfi vaccine for use in infants aged six weeks and older, expanding protection against invasive meningococcal disease caused by serogroups A, C, W and Y. MenQuadfi was previously authorized in the EU only for individuals 12 months and older, and the new indication introduces infant dosing schedules aligned with routine pediatric immunization programs. The approval is supported by the MET58 pivotal study, which evaluated immunogenicity, safety and tolerability in more than 6,000 infants across 11 countries. The decision broadens Sanofi’s vaccine portfolio and gives healthcare providers an additional option to protect infants against a rapidly progressing disease associated with high mortality and long-term complications.
Sanofi Ends Amlitelimab Development for Atopic Dermatitis After Pipeline Review
Sanofi has discontinued development of amlitelimab for atopic dermatitis following a pipeline review. The decision was based on an assessment of efficacy and safety data that indicated no meaningful improvement over current treatments. This move affects a key immunology asset and will influence how Sanofi sets its future research and development priorities. Atopic dermatitis is an important area for many drug makers given ongoing patient needs and existing biologic therapies, and this decision removes one potential future option from Sanofi's immunology portfolio.
Sanofi reports €1 billion impairment and completes €1 billion buyback
Sanofi reported €1,031 million of intangible asset impairments for the second quarter of 2026 and completed a €1,009 million share buyback covering 1.05% of its share count. The most followed narrative points to a fair value of €96.70, implying the stock is 23% undervalued compared with its last close of €74.47. The valuation case rests on steady top-line growth, rising margins, and a lower future earnings multiple, supported by innovative product launches and a strong R&D pipeline that includes multiple Phase III readouts through 2026 and expansion of biologics such as Dupixent and amlitelimab. Key risks include intensifying pricing pressure in vaccines and potential failures of late-stage pipeline assets.
Alnylam Amvuttra Revenue Surpasses $1 Billion in a Quarter for the First Time
Alnylam Pharmaceuticals reported that its drug Amvuttra exceeded $1 billion in global net product revenues in a single quarter for the first time, reaching $1.03 billion in the second quarter of 2026. Total global net product revenues were approximately $1.2 billion, a 74% increase compared to the same period last year. The company revised its full-year 2026 total net product revenue guidance to a range of $4.7 billion to $5.1 billion, citing a normalization of second-line demand growth. Non-GAAP operating income more than tripled to $318 million, while gross margin on product sales declined to 75%, down four percentage points year-over-year due to higher royalties payable to Sanofi. Alnylam also announced a strategic collaboration with B1 for exclusive commercialization and distribution rights for Amvuttra in mainland China and Macau.
Sanofi Beats Q2 Earnings and Sales Estimates but Shares Fall on Pipeline Setbacks
Sanofi reported second-quarter 2026 adjusted earnings of $1.22 per American depositary share, beating the Zacks Consensus Estimate of $1.10, while revenues of $13.48 billion surpassed the $12.73 billion consensus. Blockbuster drug Dupixent saw sales climb 37.6 percent at constant exchange rates to €5.15 billion, crossing the €5 billion quarterly mark for the first time, and the company raised its full-year 2026 sales growth outlook to around 10 percent at constant exchange rates. However, the quarter included notable pipeline setbacks, including the decision not to advance amlitelimab to regulatory submission and the discontinuation of itepekimab in chronic obstructive pulmonary disease and chronic rhinosinusitis, along with balinatunfib studies in Crohn's disease and ulcerative colitis. These setbacks resulted in more than €200 million of wind-down costs and a €952 million impairment related to amlitelimab, and despite the better-than-expected results and improved outlook, Sanofi's shares were down around 6 percent in pre-market trading.
Inflammatory Bowel Disease Market to Reach USD 21 Billion in 2025, Driven by Next-Generation Therapies
The inflammatory bowel disease market across the seven major markets was valued at USD 21 billion in 2025, with the United States accounting for the largest share. The total number of incident cases of inflammatory bowel disease in the seven major markets was around 181 million in 2025. Growth is being fueled by the rising prevalence of Crohn's disease and ulcerative colitis, increased adoption of advanced biologic therapies, and the emergence of novel mechanisms of action targeting IL-23, TL1A, and S1P pathways. Key pipeline candidates include Abivax's ABX464, Merck's Tulisokibart, RedHill Biopharma's RHB-204, and Teva Pharmaceuticals and Sanofi's duvakitug, among others. The anticipated launch of these next-generation therapies is expected to reshape the treatment landscape and address unmet needs in biologic-refractory patients.
Regeneron beats quarterly estimates on eczema drug strength, shares rise
Regeneron beat Wall Street estimates for second-quarter revenue and profit, driven by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Global net sales of Dupixent, recorded by partner Sanofi, increased 38% to about $6 billion, surpassing estimates of $5.34 billion. Quarterly U.S. sales of the high-dose Eylea rose 52% to $596 million, while the lower-dose version faced competitive pressures. The company fully repaid the Sanofi Development Balance, which RBC Capital Markets analyst Brian Abrahams said should improve margins and make second-half numbers look much better. Quarterly revenue rose 17% to $4.29 billion, exceeding estimates of $3.82 billion, and non-GAAP adjusted profit was $14.29 per share, beating the estimate of $10.26.
Sanofi Offers 5.6% Dividend Yield and Promising Growth Pipeline
Sanofi, the French pharmaceutical company, offers a 5.6% dividend yield and a total shareholder yield approaching 11% when including stock buybacks. Its top drug Dupixent saw first-quarter sales grow 31% year over year, driving overall sales up 13.6%. The stock trades at a forward price-to-earnings ratio of 9, below its five-year average of 11, and has fallen nearly 15% over the past year. Sanofi also reported five regulatory approvals in immunology during the quarter and has a pipeline of drugs in development that could offset future patent expirations.
Teva's duvakitug could drive another 50% surge as turnaround gains momentum
Teva Pharmaceutical Industries' shift from generic to branded drugs has driven an 85% share price surge over the past 12 months, and its pipeline candidate duvakitug could fuel another 50% rally. Branded drugs like Austedo, Ajovy, and Uzedy are growing sales at mid-double-digit rates, while generics now account for just over half of total revenue. Management expects 2026 earnings per share between $1.91 and $2.11, down from $2.65 in 2025 due to the dilutive impact of the Emalex Biosciences acquisition, but forecasts a 30% increase in operating profit and adjusted EBITDA starting next year. Duvakitug, co-developed with Sanofi for ulcerative colitis and Crohn's disease, is entering phase 3 trials after promising phase 2b results, with peak annual sales projected at $2 billion to $5 billion. With the stock trading at less than 10 times estimated 2027 earnings, further progress on duvakitug could trigger another major rally.
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
Scribe Therapeutics surged 67% on Friday after raising $128.7 million in an upsized initial public offering. The Alameda, California-based clinical-stage gene therapy developer opened at $25 per share, significantly above its $15 IPO price, after selling 8.58 million shares, up from the initially marketed 7.15 million shares at between $13 and $15 each. The first-day trading level gave the company a market value of approximately $440.3 million. Sanofi SA agreed through affiliates to purchase about $7.5 million of shares at the IPO price in a concurrent private placement, while existing backer Eli Lilly indicated interest in owning up to 11% of the company post-offering. Scribe, which is evaluating gene-editing technologies for atherosclerotic cardiovascular disease and expects initial trial data in the first half of 2027, reported a net loss of $17.4 million on collaboration revenue of $2.2 million for the three months ended March 31. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo led the IPO.
Sanofi halts amlitelimab development for atopic dermatitis, will not seek global regulatory approvals
Sanofi has decided to discontinue clinical development of amlitelimab for moderate-to-severe atopic dermatitis and will not submit the anti-OX40L monoclonal antibody for global regulatory evaluations. The company determined that the totality of efficacy and safety data does not support further development in this indication, as amlitelimab would not represent a meaningful improvement over standard of care despite long-term response maintenance and an emerging safety profile seen in the Phase 3 ESTUARY extension study. Sanofi will work with investigators and regulators to gradually close ongoing atopic dermatitis studies while ensuring appropriate care transitions for enrolled patients. The company reaffirmed its 2026 financial guidance and noted that a Phase 2 study of amlitelimab in celiac disease remains ongoing with results expected in the second half of 2026.
Sanofi reshapes Executive Committee ahead of next strategic chapter
Sanofi announced an evolution of its Executive Committee effective September 1, 2026, bringing together a focused leadership team as the company prepares its next strategic chapter. The new committee includes François Roger as Executive Vice President of Finance, Paulo Fontoura as Executive Vice President and Head of Research & Development, Manuela Buxo as Executive Vice President of Specialty Care, Thomas Triomphe as Executive Vice President of Vaccines, Thomas Grenier as Executive Vice President of General Medicines, Brendan O'Callaghan as Executive Vice President of Manufacturing & Supply, Jamie Haney as Executive Vice President and General Counsel, and Véronique Jaillet as Executive Vice President and Chief People Officer ad interim. Emmanuel Frenehard, Head of Digital, and Audrey Duval, Head of Corporate Affairs, will continue to report directly to CEO Belén Garijo. Madeleine Roach, currently Head of Business Operations, will become President and Country Lead of Sanofi Germany, Switzerland and Austria, while her current responsibilities will be integrated into the Finance function, which will also gain Global Partnering and Business Development. Thomas Triomphe will additionally assume responsibility for China. Olivier Charmeil, currently Executive Vice President of General Medicines, will transition to Strategic Projects Advisor to the CEO, and Roy Papatheodorou, currently Executive Vice President and General Counsel, has decided to leave the organization.
Aqemia and Sanofi expand research collaboration with new target nomination
Aqemia and Sanofi have expanded their multi-year research collaboration with the nomination of a new therapeutic target and an additional milestone payment. The partnership, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. Aqemia uses its proprietary physics-based generative AI platform, Qemi, to design novel molecules for Sanofi's targets, while Sanofi leads wet lab research, development, and commercialization. The collaboration now spans teams in Paris, London, Boston, and Frankfurt, and the new target nomination reflects growing confidence in the platform's ability to tackle difficult, first-in-class projects.
Three High-Yield Healthcare Dividend Stocks Worth Holding
Pfizer, Novo Nordisk, and Sanofi are highlighted as high-yield dividend stocks to buy and hold despite recent challenges. Pfizer offers a forward dividend yield of 7.1% and is expected to benefit from products like Padcev and Abrysvo, along with a promising pipeline in oncology and weight loss. Novo Nordisk, with a 3.6% forward yield, remains a leader in diabetes and weight loss markets and is advancing candidates such as zenagamtide and CagriSema, while also diversifying into rare blood diseases. Sanofi provides a 5.6% forward yield, driven by the strong performance of Dupixent and pipeline prospects like frexalimab, which could generate over $1 billion in peak annual sales.
Global Vaccine Sales Market to Reach US$141.40 Billion by 2036
The global vaccine sales market is projected to grow from US$76.40 billion in 2026 to US$141.40 billion by 2036, expanding at a compound annual growth rate of 6.3%. Growth is supported by rising infectious disease prevalence, broader government-funded immunisation programmes in low- and middle-income countries, and sustained investment in mRNA, viral vector, DNA and needle-free vaccine technologies. Platform-based technologies are enabling developers to pursue multiple disease targets, with programmes such as Moderna and Merck's mRNA-4157 illustrating the expanding role of mRNA in oncology. In December 2025, the Coalition for Epidemic Preparedness Innovations committed up to US$54.3 million to support a Phase III trial of Moderna's mRNA-based H5 pandemic influenza vaccine candidate, advancing the first mRNA influenza vaccine into pivotal-stage development. The market remains sensitive to U.S. tariff policies and supply-chain pressures, prompting companies to localise manufacturing and diversify suppliers. Key players include GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca and Serum Institute of India, with the report profiling 21 companies in total.
Sanofi Could Be 21% Undervalued After FDA Clears Sarclisa Escena
Sanofi stock may be undervalued by about 21% following US FDA approval of Sarclisa Escena, a subcutaneous multiple myeloma treatment that can be administered via on-body injector or manual injection. The most widely followed fair value estimate stands at €96.70 per share, well above the recent price of €76.23, even as the stock has slipped 4.94% over the past 90 days and 7.40% year-to-date. Supporters point to Sanofi's innovative pipeline, including Dupixent and amlitelimab, and multiple Phase III readouts through 2026 as drivers of long-term sales and earnings. Risks include vaccine pricing pressure and mixed late-stage trial results that could undermine the upbeat valuation case.
FDA approves Sanofi’s Sarclisa Escena as first anticancer treatment via on-body injector
The US Food and Drug Administration has approved Sanofi’s subcutaneous Sarclisa Escena for all existing multiple myeloma indications of the intravenous formulation, making it the first anticancer treatment administered through an on-body injector. The approval covers use in combination with standard-of-care regimens and is supported by the pivotal IRAKLIA phase 3 study, which showed comparable efficacy and safety to intravenous Sarclisa, with significantly shorter treatment time and fewer infusion-related reactions. In the IRAKLIA study, Sarclisa Escena via the CirCLIQ on-body injector combined with pomalidomide and dexamethasone achieved a 71.1% objective response rate versus 70.5% for the intravenous arm, while systemic administration reactions occurred in 1.5% of patients compared to 25% with intravenous infusion. The on-body injector, developed using Enable Injections’ enFuse platform, uses a retractable 30-gauge needle and is designed to deliver high-volume medicines subcutaneously with the push of a button, potentially reducing physical burden on nurses and allowing more patient interaction. Sarclisa is approved in nearly 60 countries and has been prescribed to more than 70,000 patients worldwide.
UBS backs European pharma as cleaner alternative to AI trade
UBS has reiterated its overweight stance on European pharmaceuticals, framing the sector as a more resilient home for capital than artificial intelligence at a point when the wider market is slowing. The bank argued that the investment case now rests on more than defensive quality, pointing to improving earnings revisions, low relative valuations and lighter ownership after the sector became a source of funds earlier this year. European pharma has risen more than 5% since mid-June, making it the best-performing sector over that period, and UBS described the shift as the 'what if not AI' trade with better timing. Weight-loss drugs are the strongest near-term catalyst, with the GLP-1 theme now topping UBS's ranking of investment themes in both the United States and Europe, and the bank flagged the start of Medicare coverage on 1 July as the next test of demand. UBS favours patent-light compounders such as Merck KGaA and Galderma, and among larger companies it prefers AstraZeneca and Roche, while it was more cautious on Novartis and Sanofi.
Sanofi Appoints Paulo Fontoura as Global Head of R&D Pharma
Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective September 1. Based in Paris, Fontoura will join the Executive Committee and report to CEO Belen Garijo, overseeing the company's end-to-end innovation engine from research through regulatory affairs. He succeeds Dr. Houman Ashrafian, who is leaving the company. The appointment comes as Sanofi drives an R&D transformation and advances a pipeline of new medicines across multiple therapeutic areas.
Adocia regains global rights to M1Pram as Sanofi exclusivity expires
Adocia announced the expiration of Sanofi's three-year exclusive right to negotiate a partnership for M1Pram, a fixed combination of insulin and amylin analogs for type 1 diabetes. The exclusivity was granted in July 2023 in return for a payment of €10 million. Adocia now retains global rights to M1Pram and has put its development on hold while it evaluates the path forward as the type 1 diabetes treatment landscape evolves. The company is focusing on its metabolic peptide delivery platforms, particularly BioChaperone. In a Phase 2a trial, M1Pram demonstrated a significant reduction in body weight of 5.56 kg for participants with a BMI over 30 kg/m² after 16 weeks compared to insulin lispro, along with a 21% reduction in prandial insulin doses while maintaining glycemic control without increasing hypoglycemia risk.
Kymera Therapeutics Stock Surges 51% Year to Date on KT-621 Progress
Kymera Therapeutics shares have risen 50.9% year to date, driven by rapid advancement of its lead candidate KT-621 for atopic dermatitis. The company completed enrollment in the phase IIb BROADEN2 study roughly six months ahead of schedule, pulling forward pivotal efficacy data to late 2026. Positive phase Ib data presented at the American Academy of Dermatology showed robust STAT6 degradation and a favorable safety profile, supporting KT-621 as a potential oral alternative to injectable biologics. Beyond KT-621, pipeline momentum includes dosing the first participant in a phase I trial of KT-485 under a Sanofi collaboration that triggered a $20 million milestone, new preclinical data for KT-579 in lupus models, and Gilead’s option exercise on KT-200 that brought a $45 million payment. Kymera plans to begin phase III studies in atopic dermatitis by mid-2027 and expects asthma data from the BREADTH trial in late 2027.
Sanofi's Nexviazyme meets all endpoints in infantile-onset Pompe disease study
Sanofi announced that the phase III Baby-COMET study evaluating Nexviazyme in patients with infantile-onset Pompe disease met all primary and secondary endpoints. The primary endpoint showed that treatment-naïve pediatric participants aged six months and younger remained alive and free of invasive ventilator support after 52 weeks of treatment. Secondary endpoints included the proportion of participants alive and free of invasive ventilation at 12 and 18 months of age, as well as improvements in other measures of disease progression. Based on this data, Sanofi plans to submit a regulatory filing in the United States seeking approval for Nexviazyme in infantile-onset Pompe disease in the second half of 2026. Nexviazyme is currently approved in the US for late-onset Pompe disease in patients aged one year and above, and is marketed as Nexviadyme in Europe where it is approved for both forms.
EIB grants Orano a €125 million loan for Orano Med’s cancer therapy infrastructure
The European Investment Bank has signed a €125 million credit line with Orano to finance the development of Orano Med and its industrial infrastructure, including the construction of the Advanced Thorium Extraction Facility in Bessines-sur-Gartempe, France. Orano Med, a subsidiary of the Orano group, develops lead-212-based targeted alpha therapies for cancer, with a clinical pipeline of four programs and partnerships with Sanofi, Roche, and Molecular Partners. The ATEF facility is described as the world’s first industrial site for large-scale production of thorium-228, a precursor of lead-212, and will supply all of Orano Med’s pharmaceutical production sites known as ATLabs. This is the second EIB loan to Orano in just over a year, following a €400 million agreement in March 2025 for the Georges Besse 2 uranium enrichment plant expansion.
Sanofi makes Q2 2026 aide-mémoire available ahead of July 30 results
Sanofi announced the availability of its aide-mémoire for the second quarter of 2026 results on the Investors page of sanofi.com. Prepared each quarter, the document supports financial modelling by covering non-comparable items, foreign currency impact, and share count. Sanofi's Q2 2026 results will be published on July 30, 2026.
Sanofi Stock May Be Undervalued as Fresh Drug Approvals Emerge
Sanofi's stock may be undervalued following recent drug approvals, with its price-to-earnings ratio of 18.7 times sitting below the pharmaceutical industry average of 20.7 times and a modelled fair P/E of 34.2 times. The company has secured approvals for therapies including Wayrilz, Cenrifki and Tzield, which could support future cash flows, though an ongoing European Commission antitrust probe into flu vaccine marketing presents regulatory risk. A bull case sees the stock as 22% undervalued, citing a strong pipeline with multiple Phase III readouts through 2026 and expansion of biologics like Dupixent, while a bear case flags heavy reliance on Dupixent, which generated €15.7 billion in annual sales, as a concentration risk. The stock has declined around 11.8% over the past three years, and the key question is whether the current discount reflects genuine upside or well-founded caution.
France